Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 1;48(5):393-399.
doi: 10.1097/RLU.0000000000004599. Epub 2023 Feb 8.

177Lu-DOTATATE Theranostics: Predicting Renal Dosimetry From Pretherapy 68Ga-DOTATATE PET and Clinical Biomarkers

Affiliations

177Lu-DOTATATE Theranostics: Predicting Renal Dosimetry From Pretherapy 68Ga-DOTATATE PET and Clinical Biomarkers

Avery B Peterson et al. Clin Nucl Med. .

Abstract

Purpose: Pretreatment predictions of absorbed doses can be especially valuable for patient selection and dosimetry-guided individualization of radiopharmaceutical therapy. Our goal was to build regression models using pretherapy 68Ga-DOTATATE PET uptake data and other baseline clinical factors/biomarkers to predict renal absorbed dose delivered by 177Lu-DOTATATE peptide receptor radionuclide therapy (177Lu-PRRT) for neuroendocrine tumors. We explore the combination of biomarkers and 68Ga PET uptake metrics, hypothesizing that they will improve predictive power over univariable regression.

Patients and methods: Pretherapy 68Ga-DOTATATE PET/CTs were analyzed for 25 patients (50 kidneys) who also underwent quantitative 177Lu SPECT/CT imaging at approximately 4, 24, 96, and 168 hours after cycle 1 of 177Lu-PRRT. Kidneys were contoured on the CT of the PET/CT and SPECT/CT using validated deep learning-based tools. Dosimetry was performed by coupling the multi-time point SPECT/CT images with an in-house Monte Carlo code. Pretherapy renal PET SUV metrics, activity concentration per injected activity (Bq/mL/MBq), and other baseline clinical factors/biomarkers were investigated as predictors of the 177Lu SPECT/CT-derived mean absorbed dose per injected activity to the kidneys using univariable and bivariable models. Leave-one-out cross-validation (LOOCV) was used to estimate model performance using root mean squared error and absolute percent error in predicted renal absorbed dose including mean absolute percent error (MAPE) and associated standard deviation (SD).

Results: The median therapy-delivered renal dose was 0.5 Gy/GBq (range, 0.2-1.0 Gy/GBq). In LOOCV of univariable models, PET uptake (Bq/mL/MBq) performs best with MAPE of 18.0% (SD = 13.3%), and estimated glomerular filtration rate (eGFR) gives an MAPE of 28.5% (SD = 19.2%). Bivariable regression with both PET uptake and eGFR gives LOOCV MAPE of 17.3% (SD = 11.8%), indicating minimal improvement over univariable models.

Conclusions: Pretherapy 68Ga-DOTATATE PET renal uptake can be used to predict post-177Lu-PRRT SPECT-derived mean absorbed dose to the kidneys with accuracy within 18%, on average. Compared with PET uptake alone, including eGFR in the same model to account for patient-specific kinetics did not improve predictive power. Following further validation of these preliminary findings in an independent cohort, predictions using renal PET uptake can be used in the clinic for patient selection and individualization of treatment before initiating the first cycle of PRRT.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest and sources of funding: The authors declare that they have no conflicts of interest. This work was supported by grants R01CA240706 and P30CA046592 from the National Cancer Institute.

Figures

FIGURE 1.
FIGURE 1.
Graphical overview depicting pretherapy predictive dosimetry performed with 68Ga PET uptake and biomarkers (top) and therapy-delivered dosimetry performed using serial 177Lu SPECT/CT imaging (bottom).
FIGURE 2.
FIGURE 2.
Univariable regressions for 68Ga PET-based baseline factors, which were significant (P < 0.05) for predicting therapy-delivered renal absorbed dose. Regression lines in red are fit to all n = 50 kidneys. Regression lines in black are fit to n = 48 data points that exclude the patient (indicated by the red circles) with an unusually low eGFR.
FIGURE 3.
FIGURE 3.
Univariable regressions for baseline factors retrieved from medical records, which were significant (P < 0.05) for predicting therapy-delivered renal absorbed dose. Regression lines in red are fit to all n = 50 kidneys. Regression lines in black are fit to n = 48 data points that exclude the patient (indicated by the red circles) with an unusually low eGFR.
FIGURE 4.
FIGURE 4.
Bland-Altman plots of relative percent error in LOOCV model prediction versus therapy-delivered absorbed dose with model predictions provided by (A) univariable model with PET uptake and (B) univariable model with eGFR. Horizontal axis is the therapy-delivered renal absorbed dose, and the vertical axis is the relative percent difference between LOOCV model predictions and delivered dose (ADpred,iADmeas,iADmeas,i×100%). Mean is indicated by solid horizontal line and the 95% confidence interval (mean ± 1.96 × SD) is indicated by dashed lines (n = 48 kidneys).

References

    1. Sundlöv A, Sjögreen-Gleisner K, Svensson J, et al. Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry. Eur J Nucl Med Mol Imaging. 2017;44:1480–1489. - PMC - PubMed
    1. Del Prete M, Buteau FA, Arsenault F, et al. Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial. Eur J Nucl Med Mol Imaging. 2019;46:728–742. - PubMed
    1. Roth D, Gustafsson J, Warfvinge CF, et al. Dosimetric quantities in neuroendocrine tumors over treatment cycles with 177Lu-DOTATATE. J Nucl Med. 2022;63:399–405. - PMC - PubMed
    1. Eberlein U, Cremonesi M, Lassmann M. Individualized dosimetry for theranostics: necessary, nice to have, or counterproductive? J Nucl Med. 2017;58(Suppl 2):97S–103S. - PubMed
    1. Thuillier P, Maajem M, Schick U, et al. Clinical assessment of 177Lu-DOTATATE quantification by comparison of SUV-based parameters measured on both post-PRRT SPECT/CT and 68Ga-DOTATOC PET/CT in patients with neuroendocrine tumors: a feasibility study. Clin Nucl Med. 2021;46:111–118. - PubMed

MeSH terms